Anti Factor H Antibody Positivity C5937266
A rare autoimmune disorder where antibodies target Factor H, a protein that regulates the immune complement system. This can lead to excessive complement activation and tissue damage. Management typically involves immunosuppression and sometimes complement inhibitors.
Key facts at a glance
- ICD-10
- N28.9
- ICD-11
- GA00.0
- Body system
- renal
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Hemolytic anemia
Renal dysfunction
Visual disturbances
Changes in urination or swelling
(renal)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Hypertension
(cardiovascular)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Complement inhibitor therapy
Terminal complement inhibitors like eculizumab or ravulizumab block C5 cleavage, preventing complement-mediated endothelial damage. This addresses the underlying pathophysiology of aHUS associated with anti-factor H antibodies.
Renal disease management
Active treatment with regular monitoring by a healthcare provider is recommended.
Plasma exchange
Removes anti-factor H antibodies and replaces deficient complement factors simultaneously. First-line intervention in acute settings, particularly when complement inhibitors are not immediately available.
Additional treatment options
Antihypertensive therapy
Blood pressure control with agents such as ACE inhibitors or ARBs protects renal function and addresses hypertension commonly seen with complement-mediated renal disease. Target blood pressure goals individualized based on proteinuria.
medicationRenal function and hematological monitoring
Serial monitoring of serum creatinine, eGFR, urinalysis for proteinuria, and peripheral blood counts detects disease activity and treatment response. LDH and haptoglobin monitor for hemolysis.
monitoringCorticosteroids and immunosuppressants
Adjunctive immunosuppression with corticosteroids and agents like cyclophosphamide may reduce antibody production. Used in conjunction with complement inhibitors or plasma exchange.
medicationWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Anti Factor H Antibody Positivity C5937266?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2017.
Skerka C, Józsi M, Zipfel PF, et al. Autoantibodies against complement factor H in atypical hemolytic uremic syndrome. Nat Rev Nephrol. 2018.
Fakhouri F, Delmas Y, Provot F, et al. Insights from the French National Registry of Atypical Hemolytic Uremic Syndrome: the role of anti-factor H antibodies. Blood. 2020.
Ardissino G, Testa S, Civino MP, et al. Anti-factor H antibody positivity in pediatric atypical hemolytic uremic syndrome: a systematic review and meta-analysis. J Clin Immunol. 2022.
Medication Comparisons
Compare medications used to treat Anti Factor H Antibody Positivity C5937266. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy